OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cancer is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Starting a new job	1313
New pathogen on the block	1121
Feeding latent brain metastasis	1015
An inhospitable site	936
Epigenetic remodelling drives fibroid development	882
Glycogen condensates drive tumorigenesis by trapping Hippo kinases	823
Computing brain metastasis impact	495
Breast milk for breast cancer detection	487
Fructose takes a detour to feed cancer	450
Characterization of the B cell receptor repertoire in melanoma	445
Hubs of transcriptional activity	405
To sleep, perchance to spread	396
Linking pancreatic renewal and cancer initiation	360
CAF-induced physical constraints controlling T cell state and localization in solid tumours	358
Approaching cancer during pregnancy	310
The road less travelled	298
Obesity-induced neutrophil reprogramming	292
Peto’s paradox put to the test	277
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart	266
Proximity labelling to study chromatin interactomes	265
Extrachromosomal DNA in cancer	257
The fibroinflammatory response in cancer	241
Programming immune escape	241
Cancer burden in low-income and middle-income countries	240
Quantum probes in cancer research	238

Functional lineage tracing to study the clonal evolution of therapy resistance	230
Digging for treasures in the tumour interactome	213
In vivo labelling system to study cell neighbourhoods	208
Shining a light on tumour behaviour	207
Conventional chemotherapy: millions of cures, unresolved therapeutic index	207
Publisher Correction: Programmed death ligand 1 signals in cancer cells	205
Neutrophils: a roadblock for immunotherapy	204
INVADEseq to study the intratumoural microbiota at host single-cell resolution	200
Tumour avatars to model patients’ responses to immunotherapy	197
Studying large genomic deletions with MACHETE	190
Judith Campisi (1948–2024)	187
Investigating immune cells across time in vivo	186
Revealing genomic secrets of archival FFPE samples	179
Inferring cancer metabolism from gene-expression data	175
Creating a dietary vulnerability	172
Intercepting gastric cancer	163
Rational combination of cancer therapies with PD1 axis blockade	162
Oncofetal reprogramming in tumour development and progression	156
Combinatorial strategies to target RAS-driven cancers	151
PROTACing against liver cancer	143
The language of chromatin modification in human cancers	141
The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs	140
The present and future of the Cancer Dependency Map	140
Defining and using immune archetypes to classify and treat cancer	139
Understanding tumour endothelial cell heterogeneity and function from single-cell omics	138
Dissecting metastasis using preclinical models and methods	136
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment	133
Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data	132
Polyamines in cancer: integrating organismal metabolism and antitumour immunity	130
Artificial intelligence in cancer research, diagnosis and therapy	130
Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies	129
Cancer proteogenomics: current impact and future prospects	128
Emerging strategies to investigate the biology of early cancer	124
Long noncoding RNAs in cancer metastasis	119
Tumour fatty acid metabolism in the context of therapy resistance and obesity	111
ALK in cancer: from function to therapeutic targeting	110
The dynamic role of platelets in cancer progression and their therapeutic implications	109
A standing platform for cancer drug development using ctDNA-based evidence of recurrence	109
Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance	102
Sweet success in CAR T cells	99
Cell states can give tumorigenesis a head start	96
Obesity as a promoter in BRCA mutation carriers	96
Lifestyle interventions for cancer survivors	93
Addicted to extra chromosomes	92
Switching on cancer survival mechanisms	91
Metastases arrive at other organs via bone	90
Metabolic mechanisms of medulloblastoma metastasis	85
Reflecting on 20 years of progress	84
Bidirectional CART.BiTE cells bring new hope	83
Glutamylation is good for stability	78

A machine learning toolkit for subtyping cancer in existing and new datasets	78
Translating premalignant biology to accelerate non-small-cell lung cancer interception	78
Microbiota links to immunotherapy toxicity	77
Gasdermin E shields PDAC	75
Carcinogenesis at single-cell resolution	74
The rhythm of the night	72
Finding the truth in science	70
Cholesterol-fuelled glioblastoma	69
How medical anthropology can contribute to cancer research	68
Mapping the prostate cell family tree	67
Epigenetic memory	65
Catastrophic conformity	64
Addressing systemic racism as the cancer of Black people: equity ethic-driven research	63
AR blockers augment melanoma treatment	62
The circ du RNA	61
AT1 cells appear centre stage	60
tRNA supply and demand	57
Eliminating false positives	57
Impaired RNA clearance	57
Protection against tumour formation	56
Antihistamines boost immunotherapy	56
Small speckles, big impact	55
A guide to artificial intelligence for cancer researchers	53
Epithelial and stromal co-evolution and complicity in pancreatic cancer	50
Exploiting temporal aspects of cancer immunotherapy	49
The journey from melanocytes to melanoma	48
Transfer RNAs as dynamic and critical regulators of cancer progression	48
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies	48
Targeting the DNA damage response in immuno-oncology: developments and opportunities	47
Beyond genetics: driving cancer with the tumour microenvironment behind the wheel	47
Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer	47
Tertiary lymphoid structures as hubs of antitumour immunity	46
Lighting up cancer initiation with mutant p53 reporters	45
Long-range gene regulation in hormone-dependent cancer	43
Discovering new drivers of cancer aneuploidy	40
Histological transformation to small-cell carcinoma	40
Tracing the evolutionary history of breast cancer	40
Connie J. Eaves (1944–2024)	39
VIBRANT: mapping cell phenotypes using vibrational spectroscopy	35
Patient-derived organoids unveil sarcoma vulnerabilities	33